BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38428843)

  • 1. Integrated analysis identifies cuproptosis-related gene DLAT and its competing endogenous RNAs network to predict the prognosis of pancreatic adenocarcinoma patients.
    Zhou C; Jin L; Yu J; Gao Z
    Medicine (Baltimore); 2024 Mar; 103(9):e37322. PubMed ID: 38428843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.
    Zhang X; Zhou Y; Hu J; Yu X; Xu H; Ba Z; Zhang H; Sun Y; Wang R; Du X; Mou R; Li X; Zhu J; Xie R
    BMC Cancer; 2023 Jun; 23(1):560. PubMed ID: 37330494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 4. Cuproptosis-Related Gene
    Fang Z; Wang W; Liu Y; Hua J; Liang C; Liu J; Zhang B; Shi S; Yu X; Meng Q; Xu J
    Curr Oncol; 2023 Mar; 30(3):2997-3019. PubMed ID: 36975441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-Related Genes MTF1 and LIPT1 as Novel Prognostic Biomarker in Acute Myeloid Leukemia.
    Li Y; Kan X
    Biochem Genet; 2024 Apr; 62(2):1136-1159. PubMed ID: 37561332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
    Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
    Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
    Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
    BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
    Li J; Yin J; Li W; Wang H; Ni B
    Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA LINC00857 strengthens the malignancy behaviors of pancreatic adenocarcinoma cells by serving as a competing endogenous RNA for miR-340-5p to upregulate TGFA expression.
    Li T; Zhao H; Zhou H; Geng T
    PLoS One; 2021; 16(3):e0247817. PubMed ID: 33661995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
    Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
    Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of a novel cuproptosis signature for stratifying different prognostic, immune, metabolic, and therapeutic landscapes in pancreatic adenocarcinoma.
    Yan X; Zheng W; Xu FS; Chang HL; Zhang Y; Zhang ZY; Zhang YH
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2024-2050. PubMed ID: 38497885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
    Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
    Front Genet; 2023; 14():1094793. PubMed ID: 36891150
    [No Abstract]   [Full Text] [Related]  

  • 16. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.
    Zhang N; Yu X; Sun H; Zhao Y; Wu J; Liu G
    Medicine (Baltimore); 2023 Oct; 102(42):e35167. PubMed ID: 37861553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
    Yan C; Niu Y; Li F; Zhao W; Ma L
    J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel cell cycle-related risk signature predicting prognosis in patients with pancreatic adenocarcinoma.
    Xu D; Qin R; Li M; Shen J; Mao Y; Tang K; Zhang A; Wang D; Shi Y
    Medicine (Baltimore); 2022 Nov; 101(46):e29683. PubMed ID: 36401386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissection of pyroptosis-related prognostic signature and CASP6-mediated regulation in pancreatic adenocarcinoma: new sights to clinical decision-making.
    Zhu J; Shi Y; Lan S; Wang J; Jiang F; Tang C; Cai Y; Pan Z; Jian H; Fang H; Zhang Y; Zhong F
    Apoptosis; 2023 Jun; 28(5-6):769-782. PubMed ID: 36882663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.